<SEC-DOCUMENT>0001513162-19-000029.txt : 20190125
<SEC-HEADER>0001513162-19-000029.hdr.sgml : 20190125
<ACCEPTANCE-DATETIME>20190125083022
ACCESSION NUMBER:		0001513162-19-000029
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20190125
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190125
DATE AS OF CHANGE:		20190125

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Anixa Biosciences Inc
		CENTRAL INDEX KEY:			0000715446
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MEDICAL LABORATORIES [8071]
		IRS NUMBER:				112622630
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1031

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37492
		FILM NUMBER:		19541216

	BUSINESS ADDRESS:	
		STREET 1:		3150 ALMADEN EXPRESSWAY, SUITE 250
		CITY:			SAN JOSE
		STATE:			CA
		ZIP:			95118
		BUSINESS PHONE:		408-708-9808

	MAIL ADDRESS:	
		STREET 1:		3150 ALMADEN EXPRESSWAY, SUITE 250
		CITY:			SAN JOSE
		STATE:			CA
		ZIP:			95118

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ITUS Corp
		DATE OF NAME CHANGE:	20140902

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	COPYTELE INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<head><title>Form 8-K</title> </head> <body style="FONT-SIZE:10pt; FONT-FAMILY:'Times New Roman'; MARGIN-TOP:0px; COLOR:#000000"> <p style=MARGIN:0px><br></p> <p style="FONT-SIZE:11pt; MARGIN:0px" align=center><b>UNITED STATES</b></p> <p style="FONT-SIZE:11pt; MARGIN:0px" align=center><b>SECURITIES AND EXCHANGE COMMISSION</b></p> <p style="FONT-SIZE:11pt; MARGIN:0px" align=center><b>Washington, D.C. 20549</b></p> <p style="FONT-SIZE:11pt; MARGIN:0px" align=center><b><u>&nbsp;&nbsp;&nbsp;</u></b></p> <p style=MARGIN:0px align=center><br></p> <p style="FONT-SIZE:11pt; MARGIN:0px" align=center><b>FORM 8-K</b></p> <p style=MARGIN:0px align=center><br></p> <p style="FONT-SIZE:11pt; MARGIN:0px" align=center><b>CURRENT REPORT</b></p> <p style="FONT-SIZE:11pt; MARGIN:0px" align=center><b>Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934</b></p> <p style=MARGIN:0px><br></p> <p style="FONT-SIZE:11pt; MARGIN:0px" align=center>Date of Report (Date of earliest event reported): &nbsp;January 25, 2019</p> <p style=MARGIN:0px align=center><br></p> <p style="FONT-SIZE:11pt; MARGIN:0px" align=center><b><u>ANIXA BIOSCIENCES, INC.</u></b></p> <p style="FONT-SIZE:11pt; MARGIN:0px" align=center>(Exact name of registrant as specified in its charter)</p> <p style=MARGIN:0px align=center><br></p> <table bordercolor=transparent style="FONT-SIZE:10pt; MARGIN-TOP:0px" cellpadding=0 cellspacing=0 align=center> <tr style=FONT-SIZE:0px> <td width=194> <td width=174> <td width=169 /> </tr><tr> <td width=194 style="MARGIN-TOP:0px; PADDING-BOTTOM:0px; PADDING-TOP:0px; PADDING-LEFT:4px; PADDING-RIGHT:4px" valign=top> <p style="FONT-SIZE:11pt; MARGIN:0px" align=center><b>Delaware</b></p></td> <td width=174 style="MARGIN-TOP:0px; PADDING-BOTTOM:0px; PADDING-TOP:0px; PADDING-LEFT:4px; PADDING-RIGHT:4px" valign=top> <p style="FONT-SIZE:11pt; MARGIN:0px" align=center><b>000-11254</b></p></td> <td width=169 style="MARGIN-TOP:0px; PADDING-BOTTOM:0px; PADDING-TOP:0px; PADDING-LEFT:4px; PADDING-RIGHT:4px" valign=top> <p style="FONT-SIZE:11pt; MARGIN:0px" align=center><b>11-2622630</b></p></td></tr> <tr> <td width=194 style="MARGIN-TOP:0px; PADDING-BOTTOM:0px; PADDING-TOP:0px; PADDING-LEFT:4px; PADDING-RIGHT:4px" valign=top> <p style="FONT-SIZE:11pt; MARGIN:0px" align=center>(State or other jurisdiction<br>of incorporation)</p></td> <td width=174 style="MARGIN-TOP:0px; PADDING-BOTTOM:0px; PADDING-TOP:0px; PADDING-LEFT:4px; PADDING-RIGHT:4px" valign=top> <p style="FONT-SIZE:11pt; MARGIN:0px" align=center>(Commission<br>File Number)</p></td> <td width=169 style="MARGIN-TOP:0px; PADDING-BOTTOM:0px; PADDING-TOP:0px; PADDING-LEFT:4px; PADDING-RIGHT:4px" valign=top> <p style="FONT-SIZE:11pt; MARGIN:0px" align=center>(IRS Employer</p> <p style="FONT-SIZE:11pt; MARGIN:0px" align=center>Identification No.)</p></td></tr></table> <p style=MARGIN:0px><br></p> <p style=MARGIN:0px><br></p> <table bordercolor=transparent style="FONT-SIZE:10pt; MARGIN-TOP:0px" cellpadding=0 cellspacing=0 align=center> <tr style=FONT-SIZE:0px> <td width=349> <td width=337 /> </tr><tr> <td width=349 style="MARGIN-TOP:0px; PADDING-BOTTOM:0px; PADDING-TOP:0px; PADDING-LEFT:4px; PADDING-RIGHT:4px" valign=bottom> <p style="FONT-SIZE:11pt; MARGIN:0px" align=center><b>3150 Almaden Expressway, Suite 250</b></p> <p style="FONT-SIZE:11pt; MARGIN:0px" align=center><b>San Jose, CA</b></p></td> <td width=337 style="MARGIN-TOP:0px; PADDING-BOTTOM:0px; PADDING-TOP:0px; PADDING-LEFT:4px; PADDING-RIGHT:4px" valign=bottom> <p style="FONT-SIZE:11pt; MARGIN:0px" align=center><b>95118</b></p></td></tr> <tr> <td width=349 style="MARGIN-TOP:0px; PADDING-BOTTOM:0px; PADDING-TOP:0px; PADDING-LEFT:4px; PADDING-RIGHT:4px"> <p style="FONT-SIZE:11pt; MARGIN:0px" align=center>(Address of principal executive offices)</p></td> <td width=337 style="MARGIN-TOP:0px; PADDING-BOTTOM:0px; PADDING-TOP:0px; PADDING-LEFT:4px; PADDING-RIGHT:4px"> <p style="FONT-SIZE:11pt; MARGIN:0px" align=center>(Zip Code)</p></td></tr></table> <p style=MARGIN:0px><br></p> <p style=MARGIN:0px><br></p> <p style="FONT-SIZE:11pt; MARGIN:0px" align=center>Registrant<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#146;</font>s telephone number, including area code: &nbsp;<b>(408) 708-9808</b></p> <p style=MARGIN:0px><br></p> <p style="FONT-SIZE:11pt; MARGIN:0px" align=center>(Former name or former address, if changed since last report)</p> <p style="FONT-SIZE:11pt; MARGIN:0px" align=center><b><u>&nbsp;&nbsp;&nbsp;</u></b></p> <p style=MARGIN:0px align=center><br></p> <p style="FONT-SIZE:11pt; MARGIN-BOTTOM:6px; MARGIN-TOP:6px" align=justify>Check the appropriate box below if the Form&nbsp;8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions: </p> <p style="FONT-SIZE:11pt; MARGIN-BOTTOM:6px; MARGIN-TOP:6px; PADDING-LEFT:48px"><font face=Wingdings>o</font>&nbsp;&nbsp; Written communications pursuant to Rule&nbsp;425 under the Securities Act (17&nbsp;CFR&nbsp;230.425)</p> <p style="FONT-SIZE:11pt; MARGIN-BOTTOM:6px; MARGIN-TOP:6px; PADDING-LEFT:48px"><font face=Wingdings>o</font>&nbsp;&nbsp; Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17&nbsp;CFR&nbsp;240.14a-12)</p> <p style="FONT-SIZE:11pt; MARGIN-BOTTOM:6px; MARGIN-TOP:6px; PADDING-LEFT:48px"><font face=Wingdings>o</font>&nbsp;&nbsp; Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17&nbsp;CFR&nbsp;240.14d-2(b))</p> <p style="FONT-SIZE:11pt; MARGIN-BOTTOM:6px; MARGIN-TOP:6px; PADDING-LEFT:48px"><font face=Wingdings>o</font>&nbsp;&nbsp; Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17&nbsp;CFR&nbsp;240.13e-4(c))</p> <p style="FONT-SIZE:11pt; MARGIN-BOTTOM:6px; MARGIN-TOP:6px">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter). </p> <p style="FONT-SIZE:11pt; MARGIN-BOTTOM:6px; MARGIN-TOP:6px">Emerging growth company&nbsp; <font face=Wingdings>o</font></p> <p style="FONT-SIZE:11pt; MARGIN-BOTTOM:6px; MARGIN-TOP:6px">&nbsp;</p> <p style="FONT-SIZE:11pt; MARGIN-BOTTOM:6px; MARGIN-TOP:6px">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <font face=Wingdings>o</font><br></p> <p style="FONT-SIZE:11pt; MARGIN-BOTTOM:6px; MARGIN-TOP:6px" align=center>1</p> <p style="FONT-SIZE:11pt; MARGIN-BOTTOM:6px; MARGIN-TOP:6px" align=center><hr> <DIV style="PAGE-BREAK-BEFORE: always"> </DIV></p> <p style="PAGE-BREAK-BEFORE:always; MARGIN:0px"><br></p> <p style="FONT-SIZE:12pt; MARGIN-BOTTOM:-2px; WIDTH:96px; MARGIN-TOP:0px; FLOAT:left"><b>Item 8.01</b></p> <p style="FONT-SIZE:12pt; MARGIN:0px; TEXT-INDENT:-2px" align=justify><b>Other Events</b></p> <p style="FONT-SIZE:11pt; MARGIN-BOTTOM:6px; MARGIN-TOP:6px; CLEAR:left; TEXT-INDENT:48px">On January 25, 2019, Anixa Biosciences, Inc. issued a press release announcing that it has made a recording of its January 24, 2019 conference call available on its website (such recording will be available on the company<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#146;</font>s website for 10 days) and stating certain highlights from the conference call. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.</p> <p style="FONT-SIZE:11pt; MARGIN-BOTTOM:6px; MARGIN-TOP:6px"><b>Item 9.01 Financial Statements and Exhibits.</b></p> <p style="FONT-SIZE:11pt; MARGIN:0px" align=justify>(d) Exhibits</p> <p style=MARGIN:0px align=justify><br></p> <p style="FONT-SIZE:11pt; MARGIN:0px" align=justify>The following exhibits are filed with this Current Report on Form 8-K:</p> <p style=MARGIN:0px align=justify><br></p> <p style="FONT-SIZE:11pt; MARGIN-BOTTOM:-2px; WIDTH:122px; MARGIN-TOP:0px; FLOAT:left">Exhibit No. &nbsp;&nbsp;&nbsp;&nbsp;</p> <p style="FONT-SIZE:11pt; MARGIN:0px; TEXT-INDENT:-2px" align=justify>Description</p> <p style="CLEAR:left; MARGIN:0px" align=justify><br></p> <p style="FONT-SIZE:11pt; MARGIN-BOTTOM:-2px; WIDTH:122px; MARGIN-TOP:0px; FLOAT:left">99.1</p> <p style="FONT-SIZE:11pt; MARGIN:0px; TEXT-INDENT:-2px" align=justify>Press Release dated January 25, 2019</p> <p style="FONT-SIZE:11pt; MARGIN-BOTTOM:6px; MARGIN-TOP:6px" align=center>2</p> <p style="FONT-SIZE:11pt; MARGIN-BOTTOM:6px; MARGIN-TOP:6px" align=center><hr> <DIV style="PAGE-BREAK-BEFORE: always"> </DIV></p> <p style="FONT-SIZE:11pt; MARGIN-BOTTOM:6px; MARGIN-TOP:6px" align=center>&nbsp;</p> <p style="FONT-SIZE:11pt; MARGIN:0px" align=center><b>SIGNATURES</b></p> <p style=MARGIN:0px><br></p> <p style="FONT-SIZE:11pt; MARGIN:0px; TEXT-INDENT:48px" align=justify>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style=MARGIN:0px><br></p> <p style="FONT-SIZE:11pt; MARGIN:0px">Dated: January 25, 2019</p> <p style=MARGIN:0px><br></p> <p style="FONT-SIZE:11pt; PADDING-LEFT:336px; MARGIN:0px">ANIXA BIOSCIENCES, INC.</p> <p style=MARGIN:0px><br></p> <p style="FONT-SIZE:11pt; PADDING-LEFT:336px; MARGIN:0px">&nbsp;&nbsp;&nbsp; By<u>:/s/ Amit Kumar&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </u></p> <p style="FONT-SIZE:11pt; PADDING-LEFT:336px; MARGIN:0px">&nbsp;&nbsp;&nbsp;&nbsp;Name: Dr. Amit Kumar</p> <p style="FONT-SIZE:11pt; PADDING-LEFT:336px; MARGIN:0px">&nbsp;&nbsp;&nbsp;&nbsp;Title: President and Chief Executive Officer</p> <p style="FONT-SIZE:11pt; PADDING-LEFT:0px; MARGIN:0px" align=center>3</p></body>
<!-- EDGAR Validation Code: A7C19875 -->
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit99_1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<head><title>Exhibit 99.1</title> </head> <body style="FONT-SIZE:10pt; FONT-FAMILY:'Times New Roman'; MARGIN-TOP:0px; COLOR:#000000"> <p style="FONT-SIZE:11pt; FONT-FAMILY:'Arial'; MARGIN:0px" align=right><b>Exhibit 99.1</b></p> <p style=MARGIN:0px align=center><br></p> <p style="FONT-SIZE:12pt; FONT-FAMILY:'Arial'; MARGIN:0px" align=center><b><u>Anixa Biosciences Conference Call Recording Available on Company Website</u></b></p> <p style=MARGIN:0px align=center><br></p> <p style="FONT-SIZE:11pt; FONT-FAMILY:'Arial'; MARGIN:0px" align=justify><b>SAN JOSE, Calif., January 25, 2019 /PRNewswire/</b> -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body<font style="FONT-FAMILY:Arial Unicode MS,Arial">&#146;</font>s immune system to fight cancer, today announced that it has made a recording of its January 24, 2019 conference call available on its website. &nbsp;The recording can be found on the Investor Presentation page of the company<font style="FONT-FAMILY:Arial Unicode MS,Arial">&#146;</font>s website at <font style=COLOR:#0000ff><u>www.anixa.com</u></font>. </p> <p style=MARGIN:0px align=justify><br></p> <p style="FONT-SIZE:11pt; FONT-FAMILY:'Arial'; MARGIN:0px" align=justify>During the call, Dr. Amit Kumar, President and CEO of Anixa, discussed the company<font style="FONT-FAMILY:Arial Unicode MS,Arial">&#146;</font>s plans for 2019, including the commercialization path and timeline for Cchek<sup><font size=1>TM</font></sup>, its artificial intelligence based cancer diagnostic test, and the clinical path of its CAR-T based ovarian cancer therapeutic program.</p> <p style=MARGIN:0px align=justify><br></p> <p style="FONT-SIZE:11pt; FONT-FAMILY:'Arial'; MARGIN:0px" align=justify>Highlights of the call include:</p> <p style="FONT-SIZE:11pt; FONT-FAMILY:'Arial'; PADDING-LEFT:0px; MARGIN:0px 0px 0px 0.5in; TEXT-INDENT:-0.21in" align=justify><font style="FONT-SIZE:11pt; FONT-FAMILY:Symbol">&#183;<font face=Arial>&nbsp;&nbsp;&nbsp;</font></font><font style='FONT-SIZE:11pt; FONT-FAMILY:"Arial",sans-serif'>Commercial launch of a </font><font style='FONT-SIZE:11pt; FONT-FAMILY:"Arial",sans-serif'>Cchek<sup><font style=FONT-SIZE:6pt>TM&nbsp;</font></sup></font><font style='FONT-SIZE:11pt; FONT-FAMILY:"Arial",sans-serif'>prostate cancer confirmatory test planned in the third calendar quarter of 2019;</font></p> <p style="FONT-SIZE:11pt; FONT-FAMILY:'Arial'; PADDING-LEFT:0px; MARGIN:0px 0px 0px 0.5in; TEXT-INDENT:-0.21in" align=justify><font style="FONT-SIZE:11pt; FONT-FAMILY:Symbol">&#183;<font face=Arial>&nbsp;&nbsp;&nbsp;</font></font><font style='FONT-SIZE:11pt; FONT-FAMILY:"Arial",sans-serif'>Initial </font><font style='FONT-SIZE:11pt; FONT-FAMILY:"Arial",sans-serif'>Cchek<sup><font size=1>TM </font></sup></font><font style='FONT-SIZE:11pt; FONT-FAMILY:"Arial",sans-serif'>launch as a Laboratory Developed Test under CLIA guidelines, while continuing dialogue and process with the US FDA;</font></p> <p style="FONT-SIZE:11pt; FONT-FAMILY:'Arial'; PADDING-LEFT:0px; MARGIN:0px 0px 0px 0.5in; TEXT-INDENT:-0.21in" align=justify><font style="FONT-SIZE:11pt; FONT-FAMILY:Symbol">&#183;<font face=Arial>&nbsp;&nbsp;&nbsp;</font></font>Upcoming announcement of <font style='FONT-SIZE:11pt; FONT-FAMILY:"Arial",sans-serif'>Cchek<sup><font size=1>TM </font></sup></font><font style='FONT-SIZE:11pt; FONT-FAMILY:"Arial",sans-serif'>commercialization partnership with a CLIA certified laboratory;</font></p> <p style="FONT-SIZE:11pt; FONT-FAMILY:'Arial'; PADDING-LEFT:0px; MARGIN:0px 0px 0px 0.5in; TEXT-INDENT:-0.21in" align=justify><font style="FONT-SIZE:11pt; FONT-FAMILY:Symbol">&#183;<font face=Arial>&nbsp;&nbsp;&nbsp;</font></font><font style='FONT-SIZE:11pt; FONT-FAMILY:"Arial",sans-serif'>Investigational New Drug application (IND) filing for ovarian cancer CAR-T therapy expected in the second calendar quarter of 2019; and</font></p> <p style="FONT-SIZE:11pt; FONT-FAMILY:'Arial'; PADDING-LEFT:0px; MARGIN:0px 0px 0px 0.5in; TEXT-INDENT:-0.21in" align=justify><font style="FONT-SIZE:11pt; FONT-FAMILY:Symbol">&#183;<font face=Arial>&nbsp;&nbsp;&nbsp;</font></font><font style='FONT-SIZE:11pt; FONT-FAMILY:"Arial",sans-serif'>Anticipated commencement of human clinical trials of ovarian cancer CAR-T therapy in July 2019.<font style=FONT-SIZE:11pt></font></p></font> <p style="CLEAR:left; MARGIN:0px" align=justify><br></p> <p style="FONT-SIZE:11pt; FONT-FAMILY:'Arial'; MARGIN:0px" align=justify>The recording will be available on the company<font style="FONT-FAMILY:Arial Unicode MS,Arial">&#146;</font>s website for 10 days.</p> <p style="FONT-SIZE:11pt; FONT-FAMILY:'Arial'; MARGIN:0px" align=justify>&nbsp;</p> <p style=MARGIN:0px align=justify><br></p> <p style="FONT-SIZE:11pt; FONT-FAMILY:'Arial'; MARGIN:0px" align=center>###</p> <p style=MARGIN:0px align=justify><br></p> <p style="FONT-SIZE:11pt; FONT-FAMILY:'Arial'; MARGIN:0px" align=justify><b>About Anixa Biosciences, Inc.</b></p> <p style="FONT-SIZE:11pt; FONT-FAMILY:'Arial'; COLOR:#0000ff; MARGIN:0px" align=justify><u>Anixa</u><font style=COLOR:#000000>, a cancer-focused biotechnology company, is harnessing the body<font style="FONT-FAMILY:Arial Unicode MS,Arial">&#146;</font>s immune system in the fight against cancer</font><font style=COLOR:#000000>. &nbsp;Anixa is developing both diagnostics and therapeutics to detect cancer early, when it is most curable, and to treat those afflicted once diagnosed</font><font style=COLOR:#000000>. &nbsp;It is developing the </font><font style=COLOR:#000000>Cchek</font><font size=1 style=COLOR:#000000><sup>TM</sup></font><font style=COLOR:#000000> platform, a series of </font><font style=COLOR:#000000>inexpensive </font><font style=COLOR:#000000>non-invasive blood tests for the early detection of solid tumors, which is based on the body<font style="FONT-FAMILY:Arial Unicode MS,Arial">&#146;</font>s immun</font><font style=COLOR:#000000>e</font><font style=COLOR:#000000> response to the presence of a malignancy. &nbsp;It</font><font style=COLOR:#000000> i</font><font style=COLOR:#000000>s </font><font style=COLOR:#000000>also </font><font style=COLOR:#000000>developing </font><font style=COLOR:#000000>chimer</font><font style=COLOR:#000000>ic antigen receptor T-cell (</font><font style=COLOR:#000000>CAR-T</font><font style=COLOR:#000000>)</font><font style=COLOR:#000000> based immuno-therapy drugs which genetically engineer a patient<font style="FONT-FAMILY:Arial Unicode MS,Arial">&#146;</font>s own immune cells to fight cancer. &nbsp;</font><font style=COLOR:#000000>Anixa</font><font style=COLOR:#000000> also continually examines emerging technologies in complementary or related fields for further development and commercialization. &nbsp;Additional information is available at </font><u>www.anixa.com</u><font style=COLOR:#000000>.</font></p> <p style=MARGIN:0px align=justify><br></p> <p style="FONT-SIZE:11pt; FONT-FAMILY:'Arial'; MARGIN:0px" align=justify><b><i>Forward-Looking Statements:</i></b> &nbsp;Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. &nbsp;Forward-looking statements are not statements of historical facts, but rather reflect Anixa<font style="FONT-FAMILY:Arial Unicode MS,Arial">&#146;</font>s current expectations concerning future events and results. &nbsp;We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. &nbsp;Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry </p> <p style=MARGIN:0px align=justify><br><br></p> <p> <p> <hr size=1 noshade style="MARGIN-BOTTOM:9px; PADDING-TOP:9px"> <p style="FONT-SIZE:11pt; FONT-FAMILY:'Arial'; PAGE-BREAK-BEFORE:always; MARGIN:0px" align=justify>results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. &nbsp;These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. &nbsp;We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. &nbsp;You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release. </p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style="FONT-SIZE:11pt; FONT-FAMILY:'Arial'; MARGIN:0px" align=justify>Contact:</p> <p style="FONT-SIZE:11pt; FONT-FAMILY:'Arial'; MARGIN:0px" align=justify>Mike Catelani</p> <p style="FONT-SIZE:11pt; FONT-FAMILY:'Arial'; MARGIN:0px" align=justify>(408) 708-9808</p> <p style="FONT-SIZE:11pt; FONT-FAMILY:'Arial'; COLOR:#0000ff; MARGIN:0px" align=justify><u>mcatelani@anixa.com</u></p> <p style=MARGIN:0px align=justify><br><br></p></body>
<!-- EDGAR Validation Code: EAA75B82 -->
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
